826 filings
Page 5 of 42
6-K
k02oetm28pp sw
11 Apr 23
Current report (foreign)
7:04am
6-K
zujbz4c8ijwgwo8u4l
3 Apr 23
Current report (foreign)
1:30pm
6-K
byatt9c2ti94wvttx
3 Apr 23
Securities Purchase Agreement
8:51am
424B5
vwh eix3bxz2e04
3 Apr 23
Prospectus supplement for primary offering
8:49am
6-K
08ubl6q u3n0cp6dsnz
30 Mar 23
Current report (foreign)
8:05am
6-K
8yi 9832ym4nsu622a
28 Mar 23
Current report (foreign)
4:48pm
424B3
ixgwtxm6hnwhw
22 Mar 23
Prospectus supplement
12:31pm
6-K
r4p755g0ourpzr
21 Mar 23
Current report (foreign)
7:01am
6-K
st1yg pslr
16 Mar 23
Current report (foreign)
6:16pm
6-K
63dp 070lzgdrrwep
13 Mar 23
Current report (foreign)
6:01am
6-K
1nokno036bf
8 Mar 23
Current report (foreign)
7:11pm
6-K
2rj4x noiyh
6 Mar 23
Current report (foreign)
7:09am
6-K
islrick9jlaq ep
28 Feb 23
Current report (foreign)
7:02am
6-K
1eo417
16 Feb 23
RedHill Announces Positive MHRA Meeting and Planned
8:01am
6-K
a99ajrpq7b0
15 Feb 23
RedHill Biopharma Announces Positive FDA Meeting
7:02am
6-K
oib5x9j70 1na0
6 Feb 23
RedHill Biopharma and HealthCare Royalty Agree to
7:02am
6-K
0do8zumimvraa
26 Jan 23
RedHill Receives USPTO Notice of Allowance for a Patent Covering Phase 3-stage RHB-204 for the Treatment of NTM Disease
7:02am
6-K
897t9ml dba
25 Jan 23
Current report (foreign)
9:15am
6-K
6cz31s nvwo08
24 Jan 23
Current report (foreign)
9:00am
6-K
yc55rp
3 Jan 23
RedHill Announces Publication of Positive Phase 2 Study
7:02am